Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Homerun Slides: Clinical presentation library Previous | All Articles This Week | Next
This article originally posted and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2

DCMS91HS 

Part 1 of this two-part series covers some of the newest therapies for type 2 diabetes including GLP-1 agonists and DPP-4 inhibitors. We also take a look at some of the even newer therapies on the horizon such as SGLT2 inhibitors, ultra long-acting insulin (degludec) and interleukin-1 blocker, diacerein. 

Link to download (.ppt format): Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2.

Other sets in this series:

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2

Check out all of Diabetes In Control's slide collections at our Clinical Presentations Library.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 02 July, 2012 and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?